Topiramate monotherapy in adults with newly diagnosed epilepsy.
This 6-month open-label study evaluated the efficacy and safety of topiramate monotherapy for partial-onset or primarily generalized seizures in 22 adults with newly diagnosed epilepsy. The initial topiramate dose of 25 mg could be titrated to a maximum effective or maximum tolerated dose of 200 mg/d. Eighteen patients completed the study. The mean topiramate dose was 200 mg/d (range, 75-200 mg/d). Compared with baseline, monthly seizure frequency decreased 89% (median), with 17 patients (94%) achieving complete control. Five patients dropped out of the study. No changes in hematologic, renal, and hepatic function evaluations were noted, and only 1 patient experienced clinical signs significant enough to warrant discontinuation of treatment. In this small study, topiramate in doses ranging from 75 to 200 mg/d was effective and well tolerated as monotherapy in adults with newly diagnosed epilepsy.
Salinas-estabane
Ramiro
R
Social Security System, Monterrey, Nuevo Leon, Mexico.
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D004828:Epilepsies, Partial / Q000188:drug therapy*; D004829:Epilepsy, Generalized / Q000188:drug therapy*; D005260:Female; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077236:Topiramate
D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose